Kineta Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seattle WA United States (2007)

Organization Overview

First Clinical Trial
2013
NCT02446340
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kineta Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: Kineta Inc. (2) Acquired (1)

kva12123 (1 trial)

Nesolicaftor (6 trials)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (6)

Key: Kineta Inc. (2) Acquired (4)

dalazatide (2 trials)

ethinyl estradiol (Estinyl) (1 trial)

lhf-535 (1 trial)

norgestrel (Ovral) (1 trial)

Posenacaftor (3 trials)

pti-808 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 9